Sector rotation is underway; $SPX breadth expands despite tech weakness. 19% of $SPX stocks hit 52-week highs, historically signaling gains 6-12 months out 1.
NASDAQ 100 saw an unusual -1.7% drop with more advancing stocks. This mega-tech selloff pattern, rare at 4 prior instances, consistently led to further losses in the next 2 months 2.
Indices hold, but individual stocks are slaughtered. This contrasts with 2025’s market downturn from February 19th to April 8th, prompting questions on the current bottom 3.
High-growth stocks experienced a “great purge,” with widespread 5% pullbacks and some 15-20% drops, many breaching 200-day moving averages. This presents a key “buy-the-dip” moment 4.
Big Tech is racing to fund OpenAI. Nvidia is reportedly mulling a $30 billion investment, with Amazon eyeing at least $20 billion5.
$NVDA will forego new gaming GPUs this year due to memory chip shortages. This prioritizes HBM and advanced DRAM for data center AI workloads, a strong bull signal for $MU6.
$HSY proves “boring stuff” delivers, with FY26 EPS guidance of $8.35 significantly beating the $7.06 estimate 7.
$GOOGL Search revenue jumped 17% YoY (fastest since early 2022). AI, via Gemini and AI Overviews, favorably impacts Search, indicating underappreciated growth 8.
$HIMS is launching a compounded semaglutide pill at $49 intro, then ~$99/month, severely undercutting $NVO’s Wegovy at ~$199/month for the same active ingredient 9.
$HIMS expanded into multi-cancer detection, offering $GRAIL’s Galleri blood test (screening 50+ cancers) with a $250 member discount 10.